Nasal Spray Testing: Ensuring Safety and Quality for Effective Treatments

Introduction: The Testing Framework for Nasal Drug Products

Nasal sprays are a clinically important and commercially significant dosage form — delivering active pharmaceutical ingredients directly to the nasal mucosa for local effects (treating allergic rhinitis, nasal congestion, sinusitis) and systemic absorption (delivering drugs via the highly vascularized nasal epithelium, bypassing first-pass hepatic metabolism). The global nasal drug delivery market encompasses prescription products such as intranasal corticosteroids, antihistamines, and decongestants; over-the-counter (OTC) saline and decongestant sprays; and emerging systemic delivery platforms for CNS-active compounds.

Nasal sprays are classified as Orally Inhaled and Nasal Drug Products (OINDPs) under FDA regulatory nomenclature and are subject to highly specific testing requirements that extend far beyond the generic pharmaceutical testing categories. The unique challenge of nasal spray testing is that the delivery device — the pump, actuator, bottle, and valve — is inseparable from the drug product’s performance. Testing must therefore characterize both the formulation (assay, purity, pH, osmolality, viscosity, microbial safety) and the device performance (spray pattern, plume geometry, droplet size distribution, dose uniformity, priming behavior) as an integrated system.

ContractLaboratory.com connects nasal spray manufacturers, generic drug companies, contract development and manufacturing organizations (CDMOs), and regulatory consultants with accredited pharmaceutical testing laboratories and pharmacology and drug development specialists equipped for OINDP testing. See also our related guides to compounding pharmacy USP <797> compliance, sterility testing, and USP standards testing applications.

Regulatory Framework: Key FDA Guidance Documents for Nasal Sprays

The foundation of nasal spray testing requirements in the United States is established by two primary FDA guidance documents, both from the Center for Drug Evaluation and Research (CDER):

• FDA CDER 2002 — “Nasal Spray and Inhalation Solution, Suspension and Spray Drug Products — Chemistry, Manufacturing and Controls Documentation” (CMC Guidance): Defines the CMC documentation requirements for new drug applications (NDAs) and abbreviated new drug applications (ANDAs) involving nasal spray and inhalation drug products. Specifies the characterization tests required for batch release, stability, and product lifecycle management.
• FDA CDER 2003 — “Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action” (BA/BE Guidance): The definitive guidance for in vitro and in vivo studies required to demonstrate bioequivalence between a generic nasal spray and its Reference Listed Drug (RLD). Specifies the full suite of in vitro tests — spray content uniformity, droplet size distribution, spray pattern, plume geometry, drug particle size — and the statistical framework (Population Bioequivalence, PBE analysis) for demonstrating equivalence.

For European market applications, the European Medicines Agency (EMA) Guideline on Pharmaceutical Quality of Inhalation and Nasal Products (EMEA/CPMP/QWP/49488/2003) provides the equivalent CMC requirements. While US and EU requirements are largely harmonized, some tests are jurisdiction-specific — for example, Shot Weight testing is an FDA-only requirement, while the EMA focuses on Delivered Dose Uniformity through container life.

Types of Nasal Sprays and Their Testing Implications

Nasal spray formulations fall into two primary categories, each with distinct testing requirements:

• Solution nasal sprays: The active ingredient is fully dissolved in the aqueous carrier. Testing focuses primarily on device performance characteristics (spray pattern, plume geometry, droplet size distribution by laser diffraction), formulation stability, and chemical assay. Examples: oxymetazoline (Afrin), budesonide solution (Rhinocort Aqua), ipratropium bromide solution.
• Suspension nasal sprays: The active ingredient exists as insoluble particles suspended in the aqueous carrier. This category includes the largest commercial nasal drug products — intranasal corticosteroids such as fluticasone propionate (Flonase), mometasone furoate (Nasonex), and triamcinolone acetonide (Nasacort). Suspension nasal sprays require all of the same device performance tests as solution sprays, plus drug particle size distribution (DPSD) by cascade impactor — because it is the drug particle size (not the droplet size) that determines absorption rate in the nasal mucosa for suspensions.

Complete Nasal Spray Testing Parameter Reference

Test parameter	Applicable to	Regulatory basis	Key specifications / notes
Spray Content Uniformity / Single Actuation Content (SAC)	All metered nasal sprays	USP <601>; FDA 2003 BA/BE guidance	Key specifications/notes
Droplet Size Distribution (DSD) by Laser Diffraction	Solution and suspension nasal sprays	FDA 2003 BA/BE guidance; EMA guideline	D10, D50, D90 values at two distances (2–7 cm from actuator orifice). Span = (D90-D10)/D50. PBE analysis on D50 and span for ANDA submissions.
Drug Particle Size Distribution (DPSD) by Cascade Impactor	Suspension nasal sprays only	FDA 2003 BA/BE guidance	Not less than 9 of 10 doses between 75–125% of the label claim; none outside 65–135%. Tested at beginning (B), middle (M), and end (E) lifestages. PBE analysis required for ANDA submissions.
Spray Pattern	All metered nasal sprays	FDA 2003 BA/BE guidance; EMA guideline	Cross-section of spray plume at defined distances. Key metrics: Dmax (longest diameter), Dmin (shortest diameter), ovality ratio (Dmax/Dmin). PBE analysis on ovality ratio and spray area. Measured at B lifestage for ANDA.
Plume Geometry	All metered nasal sprays	FDA 2003 BA/BE guidance	Measures the size of actual drug particles (not droplets). PBE analysis on D50 and span. Mass of drug in small particles (<9.0 μm aerodynamic diameter) is assessed using one-sided PBE.
Priming and Repriming	All metered nasal sprays	FDA 2003 BA/BE guidance; product-specific guidance	Characterizes the cone angle and width of the spray plume in the vertical plane. Key metrics: plume angle, plume width at specified distance. FDA requires plume width within 90–111% of the reference product. Measured at B lifestage. Laser imaging method.
pH	Aqueous nasal sprays	FDA CMC guidance; USP	Priming: number of actuations for consistent dose delivery on first use. Repriming: actuations needed after defined period of non-use. Tested under SAC conditions across the priming sequence.
Osmolality (Tonicity)	Aqueous nasal sprays	FDA CMC guidance	Isotonic range 270–330 mOsm/kg minimizes nasal irritation and ciliotoxicity. Hypotonic or hypertonic solutions can damage mucociliary clearance. Freezing point depression osmometry.
Viscosity	Nasal sprays with thickening agents	FDA CMC guidance	Critical for pump performance and droplet size. Higher viscosity produces larger droplets with altered deposition. Rotational viscometry at controlled temperature.
Microbial Limits / Sterility	Non-preserved: sterility required. Preserved multi-dose: microbial limits	USP <61>/<62> (microbial limits); USP <71> (sterility); FDA CMC guidance	Non-preserved unit-dose nasal sprays: sterility testing per USP <71>. Multi-dose preserved nasal sprays: total aerobic count, yeast/mold per USP <61>/<62>.
Preservative Efficacy Testing (PET)	Multi-dose preserved nasal sprays	USP <51>; Ph. Eur. 5.1.3	Target pH is typically 5.5–7.5 for nasal formulations. Affects drug stability, comfort, and mucosa compatibility. pH meters with temperature compensation.
Endotoxin Testing	Preserved aqueous nasal sprays	USP <85> (LAL test)	Bacterial endotoxin testing by Limulus Amebocyte Lysate (LAL) assay. Required for nasal sprays where the product contacts highly vascularized nasal mucosa.
Leachables and Extractables	All nasal spray container-closure systems	USP <661>; ICH Q3E; IPAC-RS best practices	Confirms antimicrobial preservative system (benzalkonium chloride, EDTA combinations, benzyl alcohol, etc.) inhibits microbial growth throughout the product use period. Inoculation with five specified organisms; count monitoring over 28 days.
Container Closure Integrity Testing (CCIT)	All nasal spray packaging systems	USP <1207>; FDA container closure integrity guidance	ICP-MS or ICP-OES for Class 1 (oral route), Class 2, and Class 3 elemental impurities. Particularly important for nasal sprays, as route-specific PDE limits apply.
Assay and Related Substances / Impurities	All nasal sprays	ICH Q6A; FDA CMC guidance; USP monograph (if applicable)	HPLC or UPLC assay for active ingredient content. Impurity profiling by HPLC-UV/HPLC-MS. Required at release and all stability time points.
Heavy Metals / Elemental Impurities	All nasal sprays	USP <232>/<233>; ICH Q3D	Characterizes the cone angle and width of the spray plume in vertical plane. Key metrics: plume angle, plume width at specified distance. FDA requires plume width within 90–111% of reference product. Measured at B lifestage. Laser imaging method.
Stability Testing	All nasal sprays (NDA/ANDA requirement)	ICH Q1A(R2); FDA stability guidance	Extraction of HDPE bottles, polypropylene pumps, elastomeric gaskets, and actuators. LC-MS/MS and GC-MS/MS identification and quantification of extractable/leachable compounds migrating into the drug product.

Key Testing Methods Explained

Spray Content Uniformity (SCU) — Dose Uniformity Through Container Life

Spray content uniformity — also called Single Actuation Content (SAC) or Delivered Dose Uniformity — is arguably the most important safety test for any metered nasal spray. It verifies that every actuation delivers a consistent and accurate dose of active ingredient throughout the product’s useful life. Per USP General Chapter <601> (Aerosols, Nasal Sprays, Metered-Dose Inhalers, and Dry Powder Inhalers), the acceptance criteria require that at least 9 of 10 tested doses fall within 75–125% of the labeled dose, with none outside the range of 65–135%.

Testing is conducted at three lifestage sampling points: beginning (B) — the first actuations from a primed pump; middle (M) — actuations at approximately the midpoint of the labeled number of doses; and end (E) — the last actuations from a container that has delivered its labeled number of doses. This lifecycle testing design detects changes in dose delivery that may occur as the pump empties and formulation consistency changes. For ANDA submissions, Population Bioequivalence (PBE) analysis is required on the SAC data to demonstrate that the generic product’s dose delivery is statistically equivalent to the reference listed drug (RLD).

Droplet Size Distribution by Laser Diffraction

Droplet size distribution (DSD) characterizes the size spectrum of spray droplets emitted by the nasal pump during actuation. This is critical because droplet size determines where in the nasal cavity the drug deposits: droplets in the appropriate size range (typically 30–200 μm for nasal sprays) deposit in the nasal turbinates, where absorption occurs, while excessively small droplets may penetrate to the lower respiratory tract, and excessively large droplets may not clear the nasal vestibule.

DSD measurement uses laser diffraction (laser diffractometry) — typically by Malvern Mastersizer, Sympatec HELOS, or equivalent instrumentation. The spray is actuated through the laser beam, and the scattering pattern produced is deconvolved to calculate the droplet volume distribution. Three parameters are reported: D10 (the diameter below which 10% of the droplet volume falls), D50 (the median volume diameter — 50% above and below), and D90 (90% cumulative volume). The span value [(D90-D10)/D50] characterizes the breadth of the distribution. Measurements are made at two distances from the actuator orifice (typically within 2–7 cm), as droplet dynamics change with distance.

Spray Pattern and Plume Geometry — Characterizing the Physical Form of the Spray

Spray pattern and plume geometry characterization are required by both the FDA and EMA for nasal spray bioequivalence studies and CMC documentation. These tests are performed using specialized laser imaging systems such as the Proveris Analytical Technologies SprayVIEW or equivalent instrumentation.

Spray pattern characterizes the cross-sectional shape of the spray plume at defined distances from the actuator orifice (typically 3 and 6 cm for nasal sprays). The spray is imaged using high-speed photography or laser-sheet imaging, and the image is analyzed for: Dmax (the longest diameter of the spray cross-section), Dmin (the shortest diameter), and the ovality ratio (Dmax/Dmin) — a measure of how circular the spray is. An ovality ratio close to 1.0 indicates a near-circular cross-section, which is associated with uniform deposition across the nasal mucosa. FDA requires PBE analysis on the ovality ratio and spray area for ANDA submissions.

Plume geometry characterizes the three-dimensional cone of the spray in the vertical plane — the plume angle and plume width at a defined distance from the actuator. Unlike the spray pattern (which does not require PBE analysis), plume geometry equivalence is assessed with the criterion that the test product’s plume angle and width fall within 90–111% of the reference product values. Plume geometry testing is performed at the beginning of the lifestage and uses the same laser imaging infrastructure as spray pattern testing.

Priming and Repriming

Priming testing establishes how many actuations are required before the pump valve is fully charged and delivers a consistent dose output — critical information for product labeling (“Prime pump before first use by actuating X times”). Repriming testing characterizes how many actuations are needed to restore consistent dosing after a defined period of non-use — this reflects the real-world scenario where a patient puts down the inhaler for several days or weeks. Both priming and repriming are tested under the same SAC conditions (dose collection apparatus, HPLC assay), and the number of actuations required to achieve label-claim dose output is established for the product labeling.

Leachables and Extractables Testing

Every material in contact with the nasal spray drug product — the HDPE bottle, the polypropylene pump housing, the elastomeric valve gaskets and seals, the actuator tip, and any metal spring components — is a potential source of extractable compounds that may migrate into the drug product during manufacture, storage, and use. Extractables are compounds that can be extracted from packaging materials under worst-case laboratory conditions (elevated temperature, aggressive solvents). Leachables are the subset of extractables that actually migrate into the drug product under normal storage and use conditions.

Testing follows USP <661> (Plastic Packaging Systems and Their Materials of Construction) and product-specific guidance. IPAC-RS has published specific best practice recommendations for leachables and extractables testing of OINDPs. Analytical methods include LC-MS/MS and GC-MS/MS for the identification of unknown compounds, and headspace GC for volatile extractables. For compounds identified at or above the Analytical Evaluation Threshold (AET), safety assessment is required per ICH Q3E.

Formulation Quality Tests: pH, Osmolality, Viscosity, and Microbial Safety

pH Testing

The pH of nasal spray formulations affects three distinct outcomes: drug stability (many APIs have pH-dependent degradation kinetics); mucosal comfort and tolerability (the human nasal cavity has a physiological pH of approximately 5.5–6.5; formulations outside the range of 5.5–7.5 may cause irritation); and the function of pH-sensitive excipients such as buffers and preservatives. pH is measured with calibrated electrochemical pH meters per USP and validated at each stability time point.

Osmolality — Tonicity Assessment

Nasal sprays should be formulated as isotonic solutions (270–330 mOsm/kg) to minimize irritation and damage to the nasal mucociliary clearance apparatus. Hypotonic solutions (below 270 mOsm/kg) cause cell swelling; hypertonic solutions (above 330 mOsm/kg) cause cell shrinkage. Both extremes can impair mucociliary transport, which is the nose’s primary defense mechanism against inhaled particles and pathogens. Osmolality is measured by freezing-point depression osmometry, comparing the freezing point depression of the formulation against calibrated standards.

Viscosity

Many nasal spray formulations incorporate thickening agents (hydroxypropyl methylcellulose, microcrystalline cellulose, carboxymethylcellulose, Avicel) to increase residence time in the nasal cavity. Viscosity is a critical quality attribute because it directly affects pump performance (higher viscosity requires more force to actuate), valve function, and droplet size distribution (more viscous formulations tend to produce larger droplets with reduced aerosol fineness). Viscosity is measured by rotational viscometry (Brookfield or equivalent) at a defined temperature (typically 20°C or 25°C) and shear rate.

Microbial Safety: Sterility, Microbial Limits, and Preservative Efficacy

Nasal drug products interface with the nasal mucosa — a highly vascularized, immunologically active tissue adjacent to the sinuses and upper respiratory tract. Microbiological safety requirements vary by product type:

• Non-preserved unit-dose nasal sprays: Must be sterile — tested per USP <71>. Single-dose containers are filled and sealed under aseptic conditions.
• Multi-dose preserved nasal sprays: Contain antimicrobial preservatives (most commonly benzalkonium chloride, typically 0.01–0.02% w/v, often with EDTA as a chelating agent). Must comply with USP <61>/<62> microbial limits testing. Additionally, require Preservative Efficacy Testing (USP <51>) — deliberate inoculation with five specified microorganisms (Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Candida albicans, Aspergillus brasiliensis) with microbial count monitoring over 28 days.
• Endotoxin testing (USP <85>, LAL assay): Bacterial endotoxin limits must be established for aqueous nasal spray formulations where the product contacts the vascular nasal epithelium. The Limulus Amebocyte Lysate (LAL) test is the standard method.

Compounded Nasal Drug Products and the Regulatory Landscape for Unapproved Peptides

Compounding pharmacies prepare customized nasal spray preparations under prescription for individual patients — regulated under Section 503A of the Drug Quality and Security Act (DQSA) for traditional pharmacies, or Section 503B for outsourcing facilities. Compounded nasal preparations must meet the sterility, potency, stability, and container-closure requirements of USP <797> (Pharmaceutical Compounding — Sterile Preparations). Testing requirements from accredited contract laboratories for compounded nasal sprays include: sterility (USP <71>), potency/assay (HPLC), pH, osmolality, endotoxin (USP <85>), and preservative efficacy where applicable.

Note on BPC-157 and unapproved synthetic peptides: Some compounding pharmacies have prepared nasal sprays containing BPC-157 (Body Protection Compound-157), a synthetic pentadecapeptide. Manufacturers and prescribers should be aware that BPC-157 is not approved by the FDA for any human use, was listed as Category 2 on the FDA’s bulk substances list (substances that may present significant safety risks), and is prohibited by the World Anti-Doping Agency (WADA) under the S0: Non-Approved Substances category. As of April 2026, the FDA removed BPC-157 from Category 2 following withdrawal of nominations, and has announced a Pharmacy Compounding Advisory Committee (PCAC) meeting for July 2026 to assess BPC-157 acetate and free base for the 503A bulks list — indicating the regulatory question remains unresolved. Compounding pharmacies that previously prepared BPC-157 formulations should consult qualified regulatory counsel on current compliance requirements. Whatever the regulatory outcome, any compounded nasal preparation must meet the same rigorous analytical testing standards described throughout this article.

Stability Testing for Nasal Sprays

Nasal spray stability programs under ICH Q1A(R2) include long-term (25°C/60% RH), intermediate (30°C/65% RH), and accelerated (40°C/75% RH) storage conditions. Uniquely for nasal sprays, the stability testing program must include device performance tests — spray content uniformity (SAC) and droplet size distribution (DSD) — at stability time points alongside the standard formulation tests (assay, impurities, pH, appearance, viscosity). This reflects that device performance can change as the formulation degrades or interacts with container-closure materials over time.

In-use stability testing is required for multi-dose nasal sprays to demonstrate that the product remains safe and effective from first use to the last actuation — including the microbiological stability of the opened container with repeated sampling. The in-use period must be supported by: preservative efficacy data, microbial limits testing, and device performance data across the full container life. See our guide to stability studies for the broader framework of pharmaceutical stability testing.

Finding Accredited Nasal Spray Testing Laboratories

OINDP testing requires highly specialized instrumentation and technical expertise not available at general pharmaceutical testing laboratories. A laboratory providing full nasal spray testing needs: laser diffraction instrumentation (Malvern, Sympatec, or equivalent) for DSD; spray pattern and plume geometry laser imaging systems (Proveris SprayVIEW or equivalent); dosage uniformity sampling apparatus for SAC/SCU; cascade impactor systems (Andersen, NGI) for drug particle size testing of suspension sprays; GC-MS/MS and LC-MS/MS for leachables and extractables; container closure integrity testing equipment; and all standard pharmaceutical analytical capabilities (HPLC/UPLC, Karl Fischer titration, viscometry, osmometry, pH meters). FDA cGMP compliance or ISO/IEC 17025 accreditation is essential for regulatory-submission-quality data.

ContractLaboratory.com connects nasal spray manufacturers, ANDA sponsors, CDMOs, and compounding pharmacies with accredited pharmaceutical testing laboratories for the full OINDP testing suite. Related resources: particle size distribution testing, heavy metals testing, sterility testing, and USP methods for pharmaceutical products.

Frequently Asked Questions About Nasal Spray Testing

Conclusion

Nasal spray testing encompasses a uniquely demanding suite of analytical requirements that extends far beyond standard pharmaceutical testing — encompassing device performance characterization (spray pattern, plume geometry, droplet size distribution, dose uniformity, priming) alongside conventional formulation quality tests (assay, pH, osmolality, viscosity, microbial safety, stability) and container-closure system evaluation (leachables/extractables, container closure integrity). The regulatory framework — anchored by FDA’s 2003 BA/BE guidance and 2002 CMC guidance, and USP General Chapter <601> — defines precise measurement requirements, lifestage sampling protocols, and statistical approaches for both brand-name NDA and generic ANDA development programs.

ContractLaboratory.com connects nasal spray manufacturers, ANDA sponsors, CDMOs, and compounding pharmacies with accredited pharmaceutical testing laboratories for the full OINDP testing suite. Submit a testing request or contact our team.